248 related articles for article (PubMed ID: 4047338)
21. Increased exocytosis of secretory granules in contrast to reduced serum hormone levels in pituitary adenomas of humans and rats treated with dopamine agonist.
Mori H; Saitoh Y; Maeda T; Okada Y; Hirano H; Tsuji M
Med Electron Microsc; 2001 Jun; 34(2):123-33. PubMed ID: 11685661
[TBL] [Abstract][Full Text] [Related]
22. Difference of lectin binding sites of secretory granules between normal pituitary and adenoma cells.
Hori T; Nishiyama F; Anno Y; Adachi S; Numata H; Hokama Y; Muraoka K; Hirano H
Acta Neuropathol; 1985; 66(3):177-83. PubMed ID: 2990144
[TBL] [Abstract][Full Text] [Related]
23. Pathology of prolactin cell adenomas of the human pituitary.
Horvath E; Kovacs K
Semin Diagn Pathol; 1986 Feb; 3(1):4-17. PubMed ID: 3303229
[TBL] [Abstract][Full Text] [Related]
24. In-vitro effects of bromocriptine on isolated pituitary adenoma cells. Ultrastructural and morphometrical studies.
Saeger W; Thiel M; Caselitz J; Lüdecke DK
Pathol Res Pract; 1985 Dec; 180(6):697-704. PubMed ID: 3832005
[TBL] [Abstract][Full Text] [Related]
25. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.
Osamura RY; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530
[TBL] [Abstract][Full Text] [Related]
26. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
27. Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells.
Johansen PW; Haug E; Gautvik KM
Acta Endocrinol (Copenh); 1985 Oct; 110(2):200-6. PubMed ID: 4060970
[TBL] [Abstract][Full Text] [Related]
28. Decreased prolactin level in secretory granules and their increased exocytosis in estrogen-induced pituitary hyperplasia in rats treated with a dopamine agonist.
Maeda T; Sawada K; Itoh Y; Moriwaki K; Mori H
Lab Invest; 1991 Dec; 65(6):679-87. PubMed ID: 1753713
[TBL] [Abstract][Full Text] [Related]
29. Prolactin and growth hormone-producing pituitary adenomas. An immunohistochemical and ultrastructural study.
Lloyd RV; Gikas PW; Chandler WF
Am J Surg Pathol; 1983 Apr; 7(3):251-60. PubMed ID: 6340535
[TBL] [Abstract][Full Text] [Related]
30. Pituitary adenomas producing growth hormone in acromegalic patients.
Smallman LA; Dunn PJ; Curran RC; London DR
J Clin Pathol; 1984 Apr; 37(4):382-9. PubMed ID: 6368603
[TBL] [Abstract][Full Text] [Related]
31. Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists.
Schottke H; Saeger W; Lüdecke DK; Caselitz J
Pathol Res Pract; 1986 Jun; 181(3):280-90. PubMed ID: 3748874
[TBL] [Abstract][Full Text] [Related]
32. Transformation of a human mixed GH-PRL adenoma cell population in response to long-term bromocriptine treatment.
Bácsy E; Fazekas I; Slowik F; Pásztor E; Czirják S
Folia Histochem Cytobiol; 1997; 35(2):69-74. PubMed ID: 9151080
[TBL] [Abstract][Full Text] [Related]
33. Morphological effects of octreotide on growth hormone-producing pituitary adenomas.
Ezzat S; Horvath E; Harris AG; Kovacs K
J Clin Endocrinol Metab; 1994 Jul; 79(1):113-8. PubMed ID: 8027215
[TBL] [Abstract][Full Text] [Related]
34. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.
Mori H; Mori S; Saitoh Y; Arita N; Aono T; Uozumi T; Mogami H; Matsumoto K
Cancer; 1985 Jul; 56(2):230-8. PubMed ID: 4005795
[TBL] [Abstract][Full Text] [Related]
35. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
36. Ultrastructural localization of prolactin in the human pituitary prolactinomas and its changes by bromocriptine treatment.
Osamura RY; Teramoto A; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1123-30. PubMed ID: 3776529
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology.
Yamada S; Aiba T; Sano T; Kovacs K; Shishiba Y; Sawano S; Takada K
Neurosurgery; 1993 Jul; 33(1):20-7. PubMed ID: 7689191
[TBL] [Abstract][Full Text] [Related]
38. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
39. Mixed growth hormone- and prolactin cell adenomas of the pituitary gland. An immunoelectron microscopic study.
Holm R; Nesland JM; Attramadal A; Reinli S; Johannessen JV
J Submicrosc Cytol Pathol; 1989 Apr; 21(2):339-50. PubMed ID: 2752363
[TBL] [Abstract][Full Text] [Related]
40. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
Barbarino A; de Marinis L; Menini E; Anile C; Maira G
Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
